Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof

Abstract

The invention relates to the molecule having formula (I), as well as the enantiomers thereof, and to the use of same in the treatment of ADHD, narcolepsy or idiopathic hypersomnia.

1 - 14 . (canceled) 
     
     
         15 . A method of treating narcolepsy or idiopathic hypersomnia comprising administering an effective amount of a compound, or a pharmaceutically acceptable salt thereof, of the following formula: 
       
         
           
           
               
               
           
         
       
       as the (R) enantiomer in an enantiomeric excess of more than 95% to a patient in need thereof. 
     
     
         16 . The method according to  claim 15 , wherein the (R) enantiomer compound, or a pharmaceutically acceptable salt thereof, is in an enantiomeric excess of more than 99%. 
     
     
         17 . The method according to  claim 15 , wherein the effective amount is from 1 to 400 mg. 
     
     
         18 . The method according to  claim 15 , wherein from 1 to 400 mg of the (R) enantiomer compound, or a pharmaceutically acceptable salt thereof, is administered to the patient per day. 
     
     
         19 . The method according to  claim 15 , wherein from 200 to 300 mg of the (R) enantiomer compound, or a pharmaceutically acceptable salt thereof, is administered to the patient per day. 
     
     
         20 . The method according to  claim 15 , wherein the (R) enantiomer compound, or a pharmaceutically acceptable salt thereof, is administered to the patient orally. 
     
     
         21 . The method according to  claim 15 , wherein the patient is a child. 
     
     
         22 . The method according to  claim 15 , wherein the patient is also administered concomitantly, separately or sequentially, iron, one or more psychostimulants, one or more serotoninergic antidepressants, or sodium gamma-hydroxybutyrate. 
     
     
         23 . The method according to  claim 15 , wherein the (R) enantiomer compound, or a pharmaceutically acceptable salt thereof, is in a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients. 
     
     
         24 . The method according to  claim 23 , wherein the pharmaceutical composition is a tablet. 
     
     
         25 . The method according to  claim 23 , wherein the pharmaceutical composition further comprises iron, one or more psychostimulants, one or more serotoninergic antidepressants, or sodium gamma-hydroxybutyrate.